3,4-Dicaffeoylquinic Acid, a Major Constituent of Brazilian Propolis, Increases TRAIL Expression and Extends the Lifetimes of Mice Infected  with the Influenza A Virus by Takemura, Tomoaki et al.
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2012, Article ID 946867, 7 pages
doi:10.1155/2012/946867
Research Article
3,4-DicaffeoylquinicAcid,a Major Constituent of Brazilian
Propolis,IncreasesTRAIL Expressionand Extendsthe Lifetimes
of Mice Infectedwith the InﬂuenzaA Virus
Tomoaki Takemura,1 Tomohiko Urushisaki,1 MayukoFukuoka,2,3
Junji Hosokawa-Muto,4,5 Taketoshi Hata,1 Yumiko Okuda,4 Sachie Hori,4 Shigemi Tazawa,1
Yoko Araki,1 andKazuoKuwata2,3,4
1Nagaragawa Research Center, API Co., Ltd., 692-3 Nagara, Gifu 502-0071, Japan
2United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, 1-1 Yanagido,
Gifu 501-1193, Japan
3CREST, Japan Science and Technology Agency, 4-1-8 Honcho, Kawaguchi, Saitama 332-0012, Japan
4Center for Emerging Infectious Diseases, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan
5First Department of Forensic Science, National Research Institute of Police Science, 6-3-1 Kashiwanoha, Kashiwa, Chiba
277-0882, Japan
Correspondence should be addressed to Kazuo Kuwata, kuwata@gifu-u.ac.jp
Received 12 May 2011; Revised 4 July 2011; Accepted 4 July 2011
Academic Editor: Vincenzo De Feo
Copyright © 2012 Tomoaki Takemura et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Brazilian green propolis water extract (PWE) and its chemical components, caﬀeoylquinic acids, such as 3,4-dicaﬀeoylquinic acid
(3,4-diCQA), act against the inﬂuenza A virus (IAV) without inﬂuencing the viral components. Here, we evaluated the anti-IAV
activities of these compounds in vivo. PWE or PEE (Brazilian green propolis ethanol extract) at a dose of 200mg/kg was orally
administered to Balb/c mice that had been inoculated with IAV strain A/WSN/33. The lifetimes of the PWE-treated mice were
signiﬁcantly extended compared to the untreated mice. Moreover, oral administration of 3,4-diCQA, a constituent of PWE, at
a dose of 50mg/kg had a stronger eﬀect than PWE itself. We found that the amount of tumor necrosis factor-related apoptosis-
inducingligand(TRAIL)mRNAinthemicethatwereadministered3,4-diCQAwassigniﬁcantlyincreasedcomparedtothecontrol
group,whileH1N1hemagglutinin(HA)mRNAwasslightlydecreased.ThesedataindicatethatPWE,PEEor3,4-diCQApossesses
a novel and unique mechanism of anti-inﬂuenza viral activity, that is, enhancing viral clearance by increasing TRAIL.
1.Introduction
Inﬂuenza is a common infectious disease, and various anti-
inﬂuenza drugs are already on the market. For example,
M2 ion channel inhibitors (amantadine and rimantadine)
and neuraminidase inhibitors (zanamivir, oseltamivir, etc.)
have been used to treat inﬂuenza viral infections in many
areas, including the United States, Europe, and Asia [1–
3]. Although oseltamivir is one of the most popular anti-
inﬂuenza drugs, many resistant strains have already been
discovered [4, 5]. Fortunately, the resistant strains that have
been found to date are not yet pandemic. However, we
need to carefully monitor the emergence and prevalence
of new strains with pandemic characteristics, such as the
H1N1 pandemic with drug resistance, which may occur
because of the high incidence of mutations [6] and genomic
rearrangements [7]. To avoid the worst, the discovery of
novel anti-inﬂuenza agents that do not carry the risk of
creating resistant strains would be urgently required.
Propolis, a resinous substance collected by honeybees
from various plant sources, is used by the bees to protect the
nest entrance against intruders and bacteria. Since ancient
times, it has been used as a traditional folk medicine in many
countries. Recent studies have demonstrated that propolis
has a wide range of pharmacological properties, including
antibacterial [8–10], antioxidant [11], anti-inﬂammatory2 Evidence-Based Complementary and Alternative Medicine
[12], and antitumor activities [13]. The activity and con-
stituents of propolis vary with its geographical origin [14].
The diﬀerences in its constituents arise from diﬀerences in
the plants from which it is sourced [15].
The antiviral activity of propolis has been reported and
includes anti-BBMV [16], anti-HSV [17–21], antipoliovirus
[22], anti-IBDV [10], anti-reovirus [10], antipotato viruses
[23],andanti-HIV[24]activities[25,26].Theanti-inﬂuenza
activity of propolis has been also described in several reports
[27–30], but the details of its activity were diﬀerent. The
reason for this may be diﬀerences in the plant origin of the
propolis [14].
Recently, we have demonstrated that Brazilian green
propolis water extract (PWE) and its components, partic-
ularly 3,4-dicaﬀeoylquinic acid (3,4-diCQA), have anti-IAV
activity [31]. Moreover, we found that a central mechanism
of these compounds is the enhancement of cellular viability
via unknown cellular processes rather than activity against
the viral components [31].
Here, we examined the in vivo eﬀects of propolis extracts
on the lifetimes of mice infected with the IAV. To obtain
insights into the mechanism of the antiviral eﬀects of
PWE and PEE, we examined tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) and IAV hemagglutinin
(HA) gene expression in the lungs, because it has been
reported that the ethanol extract of Polish propolis has anti-
tumor activity via TRAIL enhancement [32].
2. Methods
2.1. Reagents and Compounds. Oseltamivir phosphate (Tam-
iﬂu) was purchased from the Chugai Pharmaceutical Co.,
Ltd. (Tokyo, Japan). Chlorogenic acid was purchased from
the Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). All
media and reagents for cell culture were purchased from
Invitrogen (Carlsbad, CA, USA), Sigma (St. Louis, MO,
USA), and Wako Pure Chemicals (Osaka, Japan). Water
extracts of Brazilian green propolis (Minas Gerais State,
Brazil) originating from Baccharis dracunculifolia [33]w e r e
obtained from the API Co., Ltd. (Gifu, Japan). 3,4-diCQA
(99% or 82% purity) was puriﬁed from 25% ethanol-
extracted Brazilian green propolis via column chromatogra-
phy and HPLC (details not shown).
2.2. Mice. Female BALB/c mice (5 weeks old) were obtained
from Japan SLC, Inc. (Hamamatsu, Japan) and housed at
room temperature (maintained at 23 ± 3◦C) with a relative
humidity range of 32–64% and a regular 12hr light/dark
cycle.ThemicewerefedaCE-2rodentdietfromCLEAJapan
Inc. (Tokyo, Japan) and allowed free access to water.
2.3. Viruses. The inﬂuenza virus wild-type strain A/WSN/33
(H1N1), generated from cloned cDNAs using plasmid-based
reverse genetics [34], was kindly supplied by Dr. Yoshihiro
Kawaoka(DivisionofVirology,DepartmentofMicrobiology
and Immunology, Institute of Medical Science University of
Tokyo, Japan). The viruses were stored at −80◦C until use.
2.4. Cells. Madin-Darby canine kidney (MDCK) cells were
a kind gift from Professor Hideto Fukushi (United Grad-
uate School of Veterinary Sciences, Gifu University) and
were maintained in α-minimal essential medium (MEM)
containing 10% fetal bovine serum (FBS) and penicillin-
streptomycin.
2.5. Virus Preparation in Cell Culture and Determination
of the TCID50 Value. M D C Kc e l l sw e r ec u l t u r e di nT - 7 5
culture ﬂasks. Conﬂuent cells were washed with phosphate-
buﬀered saline (PBS) and then incubated with the virus (0.1
multiplicity of infection (MOI)) in 2mL of viral growth
medium (D-MEM (Dulbecco’s Modiﬁed Eagle Medium)
containing 0.625μg/mL of trypsin and 0.1% bovine serum
albumin (BSA)) for 1hr at 37◦C. Then, 10mL of viral
growth medium was added, and the cells were incubated for
24hrs at 37◦C. The culture supernatant was harvested by
centrifugation (3000rpm at 4◦C) and stored at −80◦C until
use. TCID50 (50% tissue culture infective dose) values were
determined by infecting the MDCK cells with serial dilutions
of the viral suspension in 96-well microtiter plates, and the
TCID50 values were calculated using the method of Reed and
Muench [35]a f t e r6d a y s .
2.6. Mouse Adaptation and Preparation of Virus. Viruses that
had been passaged 2 or 3 times in MDCK cells were further
seriallypassagedin6-week-oldfemaleBALB/cmice.Theﬁrst
passaged virus lot was obtained by intranasally inoculating a
20-μL suspension of the starting virus (5.1 × 108 TCID50 per
mL) into each animal, which had been lightly anesthetized
using diethyl ether. At 48hrs postinoculation (hpi), the mice
were sacriﬁced. Their lungs were removed, placed into PBS
(2mL for the lungs of two mice) supplemented with 0.1%
BSA and penicillin-streptomycin, and homogenized using
a PRO200 homogenizer (PRO Scientiﬁc Inc.; Oxford, CT,
USA). The suspension was further centrifuged at 3000rpm
at 4◦C, stored at −80◦C, and termed MP1 (mouse passage
1). The subsequent passages were similarly performed by
inoculating40μLoftheviralsolutionofthepreviouspassage
into each mouse. The second- and higher-passage virus lots
were termed MP2, MP3, and so forth.
2.7. Anti-Inﬂuenza Therapeutic Eﬃcacy in Mice
2.7.1. Assessment of Survival Time. Six-week-old female
BALB/c mice were lightly anesthetized with diethyl ether
and inoculated with 40μL of a mixture of MP6 to MP12
(i.e., mouse-adapted viruses (8.3–53 × 104 TCID50/mouse,
resp.)) once per day for 4 days via intranasal instillation. The
mice were categorized into 6 groups: (1) control (vehicle);
(2) oseltamivir phosphate (0.5mg/kg of body weight); (3)
PWE (100mg/kg); (4) PEE (100mg/kg); (5) 3,4-diCQA
(99% purity; 50mg/kg); (6) chlorogenic acid (50mg/kg).
The compounds (in a 5% Arabic gum solution) were orally
administered to the mice twice per day at intervals of more
than 6hrs for 6 days (from 0 to 5dpi (days postinfection)).
Administration began 4hrs before viral inoculation. Mouse
survival was observed once per day for 12 days after viral
inoculation.
2.7.2. Assessment of mRNA Expression in the Lungs. Six-
week-old female BALB/c mice were lightly anesthetized withEvidence-Based Complementary and Alternative Medicine 3
diethyl ether and inoculated with 20μL of MP14, a mouse-
adapted virus (4.9 × 105 TCID50/mouse) once per day for
2 days via intranasal instillation. The mice were categorized
into three groups: (1) control (vehicle); (2) 3,4-diCQA (82%
purity; 50mg/kg); (3) oseltamivir phosphate (0.5mg/kg).
Each compound (in a 5% Arabic gum solution) was orally
administered to the mice twice per day at 6-hour intervals
for 8 days (from 0 to 7dpi). Administration began 4 hrs
before viral inoculation. In the mRNA expression study
(n = 13–14 at 0dpi), the 6 mice with the lowest body weight
in each group and the remaining surviving mice in each
group were killed at 4 and 7dpi, respectively, and the mRNA
expression in the lungs was determined using quantitative
real-time PCR (qPCR), as described below.
Total RNA was extracted from the lung homogenate
using the TriPure Isolation Reagent (Roche Diagnostics,
Mannheim, Germany), according to the manufacturer’s
protocol. Brieﬂy, the mice were sacriﬁced, and their lungs
were removed, placed into a solution (1.5mL for the
lungs of one mouse) of TriPure, and homogenized using
a PRO200 homogenizer. After centrifugation, the water
phase of the lysate was recovered, and RNA was precip-
itated with the ethanol and rinsed. The puriﬁed RNA
was dissolved in 50–100μL of nuclease-free water. The
amount of RNA was estimated using a NanoDrop (Thermo
Scientiﬁc, Wilmington, DE, USA). The cDNA from a 500-
ng aliquot was synthesized using a PrimeScript RT reagent
kit (Takara Bio Inc., Shiga, Japan) and oligo dT primers
as RT (reverse transcription) primers, according to the
manufacturer’s protocol. Quantitative real-time PCR for
the IAV or mouse gene was then performed. Brieﬂy, the
aliquot of the RT reaction solution was ampliﬁed using
SYBR Premix Ex Taq II (Takara Bio Inc., Shiga, Japan)
and a Real-Time PCR Thermal Cycler (“Thermal Cycler
Dice Real Time,” Takara Bio Inc., Shiga, Japan), accord-
ing to the manufacturer’s protocol. H1N1-speciﬁc primers
were selected based on HA (hemagglutinin) mRNA using
Primer Express software (PE Applied Biosystems, Waltham,
MA, USA). The sequences of the HA primer sets were
5 -CAATGTATGCTTTCGCACTGAGTA-3  for the forward
primer and 5 -GACACTTCGTGTTACACTCATGCA-3  for
the reverse primer. The sequences of the mouse TRAIL
primer sets have been described elsewhere [36]. The mouse
HPRT (hypoxanthine guanine phosphoribosyl transferase)
primer sets were purchased from Takara Bio Inc. (Shiga,
Japan). The relative quantities of H1N1 HA mRNA and
mouse TRAIL mRNA were normalized to the mRNA
expression of mouse HPRT (a housekeeping gene).
2.8. Statistics. The survival times were statistically com-
pared using the Kaplan-Meier log-rank test and pairwise
multiple comparison procedures (the Holm-Sidak method)
using StatView 3.5 (SAS Institute, Cary, NC, USA). The
body weights were compared using one-way analysis of
variance (ANOVA). When any signiﬁcance was detected by
ANOVA, Dennett’s nonparametric test was then applied
using Ekuseru-Tokei 2006 (Social Survey Research Informa-
tion Co., Ltd., Tokyo Japan). The relative mRNA expression
of the target gene was compared between treatment groups
using a paired t-test or Student’s t-test. A P value of less than
0.01 (P<0.01) was considered to be statistically signiﬁcant.
3. Results
3.1. PWE, PEE, and 3,4-diCQA Increase the Survival Times
of Mice Infected with the Inﬂuenza Virus. In preliminary
experiments, MDCK culture-derived WSN/33 (H1N1, IAV)
was only moderately lethal to mice, so we adapted the
parent WSN/33 to mice using serial passages to enhance
its virulence [37–39], as described in the Section 2. Mouse-
adapted WSN/33 was able to kill more than 80% of mice
within 10 days when the mice inoculated daily for 3 to 4
days. The anti-inﬂuenza activities of PWE, PEE, 3,4-diCQA,
chlorogenic acid, and oseltamivir phosphate were evaluated
using the mouse-adapted WSN/33 strains.
Thevehicletreatment(control)groupexhibitedasigniﬁ-
cant decrease in body weight from 0 to 7dpi. Treatment with
PWE, PEE, or chlorogenic acid did not aﬀect this phenotype
compared to the control. However, 3,4-CQA (at 5 dpi alone,
P<0.01) and oseltamivir (at 5dpi, P<0.05; at 6-7dpi,
P<0.01) slightly and strongly, respectively, counteracted the
body weight loss caused by the viral infection (Figures 1(a)
and 1(b)).
In the same experiment, 88.9% of mice in the control
group died by 12dpi, while all of the oseltamivir-treated
mice survived. The survival time of the oseltamivir group
was signiﬁcantly longer than that of the control group
(Figure 2(a), Table 1). Moreover, although chlorogenic acid
had no eﬀect, PWE, PEE, or 3,4-CQA treatment increased
the survival rate (Figures 2(a) and 2(b), Table 1).
3.2. 3,4-diCQA Increases TRAIL Expression but Decreases
HA mRNA Expression in Mouse Lungs Infected with IAV.
We examined TRAIL and HA mRNA expression in the
lungs of mice infected with IAV. Treatment with 3,4-CQA
or oseltamivir had no eﬀect on TRAIL mRNA expression
at 4dpi (Figure 3). At 7dpi, the 3,4-CQA treatment group
exhibitedanincreaseinTRAILmRNAexpression(P<0.05),
whiletheoseltamivirtreatmentgroupexhibitednochangein
the expression of TRAIL mRNA (Figure 3).
In the same experiment, the oseltamivir treatment group
exhibitedlessHAmRNAexpressionthanthecontrolat4and
7dpi (P<0.05; Figure 4). The 3,4-diCQA treatment group
exhibited similar HA mRNA expression at 4dpi and slightly
less expression at 7dpi than the control group (Figure 4).
Overall, oseltamivir treatment decreased IAV HA mRNA
expressionrapidlyafterinfectionandhadnoeﬀectonTRAIL
mRNA expression, whereas 3,4-diCQA treatment moder-
ately decreased IAV HA mRNA expression and increased
TRAIL mRNA expression with a delay.
4. Discussion
First, we must point out that there are some controversies
regarding the anti-inﬂuenza eﬀects of various propolis-
related substances, especially in ex vivo versus in vivo
experiments. We have shown that PWE and PEE can increase4 Evidence-Based Complementary and Alternative Medicine






















































Figure 1: Eﬀects of orally administrated oseltamivir phosphate, PWE, PEE, 3,4-diCQA, and chlorogenic acid on the body weight of
BALB/c mice infected with the IAV. (a) control (), oseltamivir (0.5mg/kg; ), 3,4-diCQA (50mg/kg; ), (b) PWE (100mg/kg; ), PEE
(100mg/kg; ), or chlorogenic acid (50mg/kg; ) was administrated twice daily starting at 4hours before the ﬁrst viral infection until 5
days postinfection (5dpi). The data represent the mean ± SE for the mice that survived. ∗P<0.05 and ∗∗P<0.01 versus vehicle control.


































Figure 2: Survival curves of BALB/c mice infected with the IAV to assess the in vivo eﬀects of orally administrated (a) control, oseltamivir
(0.5mg/kg),3,4-diCQA(50mg/kg),(b)PWE(100mg/kg),PEE(100mg/kg),orchlorogenicacid(50mg/kg).Thecolorscorrespondtothose
used in Figures 1(a) and 1(b). The infected mice were observed for 12 days. The statistical results are shown in Table 1.
the lifetimes of mice with IAV infections. In a previous
report, anti-inﬂuenza activity was found for PWE [31]b u t
not PEE (personal communication, Urushisaki T.) when
using MDCK cells. Here, we speculate that, in ex vivo
experiments, some substances (as yet unidentiﬁed) in PEE
are cytotoxic to MDCK cells and may mask its anti-inﬂuenza
activity. We have also shown that 3,4-diCQA can increase the
lifetimes of mice with IAV infections (Table 1). 3,4-diCQA,
a natural product, is an ester of two polyphenolic caﬀeic
acids and one cyclitol (−)-quinic acid. While chlorogenic
acid (a natural product, an ester of one caﬀeic acid and
one cyclitol (−)-quinic acid) does not have anti-inﬂuenza
activity in vivo, these two compounds have anti-inﬂuenza
activity ex vivo [31]. This may occur due to diﬀerences in the
pharmacokinetic properties of these compounds in vivo.
The major chemical ingredients in PWE and PEE are
listed in Table 2 [40, 41], and these show that the amount
of 3,4-diCQA in PWE and PEE is 3.3–6.1% and 1.9–
3.5%, respectively. It must be noted that the anti-inﬂuenza
activities of PWE and PEE can only be partially explained by
3,4-diCQA. Thus, it is very likely that unknown compounds
that eﬃciently act against the IAV are also contained in PWE
and PEE.
We have also shown that 3,4-diCQA increases the mRNA
expression of TRAIL in the lungs of IAV-infected mice
(Figure 4). Although TRAIL is an apoptosis-inducing factor
in tumor cells [42], it also induces the apoptosis of inﬂuenza
virus-infected cells in infected animals via the TRAIL recep-
tor(DR5),whoseexpressionisinducedbythevirus.Ishikawa
et al. [36] have shown that TRAIL mRNA expression is
induced by an inﬂuenza virus infection in mouse lungs,
and an anti-TRAIL monoclonal antibody (mAb) delays
inﬂuenza virus clearance in mice. Moreover, Brincks et al.
[43] have shown that morbidity and the inﬂuenza virusEvidence-Based Complementary and Alternative Medicine 5
Table 1: Survival of mice infected with IAV after the oral administration of various substances.
Treatment n Dose Duration (dpi) Survival time (dpi, mean ± SE) Statistical signiﬁcance
5% Arabic gum 9 0–5 7.4 ± 0.7
oseltamivir 8 0.5mg twice/kg/day 0–5 >12.0# ∗∗
PWE 9 100mg twice/kg/day 0–5 10.0 ± 0.9 ∗
PEE 9 100mg twice/kg/day 0–5 10.1 ± 0.9 ∗
3,4-diCQA 7 50mg twice/kg/day 0–5 10.3 ± 1.5 ∗
Chlorogenic acid 9 50mg twice/kg/day 0–5 8.1 ± 0.8 N.S.




















































































Figure 3: TRAIL expression in the lungs of BALB/c mice infected
with the IAV. Vehicle, 3,4-diCQA (50mg/kg), or oseltamivir
(0.5mg/kg) was administrated twice daily starting at 4hrs before
the ﬁrst viral infection until 7days post-infection (7dpi). Total
RNA was recovered at 4dpi or 7dpi, and relative mRNA expression
was measured using real-time PCR. The quantity of mouse TRAIL
mRNA expression was normalized to the mRNA expression of
mouse HPRT. The quantities are shown as mean ± SE. ∗∗P<0.01.
titer are increased in TRAIL-knockout (TRAIL−/−)m i c e .
Therefore, TRAIL is an important anti-inﬂuenza factor with
viral clearance activity.
3,4-diCQA did not aﬀect TRAIL expression at 4dpi
(Figure 3). However, the infected animals were protected
evenatearlystagesoftheinfectiousperiodwithoutincreased
TRAIL expression because 3,4-diCQA increases the viability
ofinfectedcells,assuggestedbypreviousexvivoexperiments
[31]. It must be noted that MDCK cells do not express
the TRAIL receptor [44]. 3,4-diCQA induced TRAIL mRNA
at 7dpi relative to the control group (Figure 3). During
the middle stage of infection, TRAIL expression increased,
thereby increasing the lifetimes of the mice.
It has also been reported that the induction of TRAIL
mRNA depends on NF-κB[ 45]. However, at the current
stage, it is unclear whether the enhancement of TRAIL




















































































Figure 4: HA expression in lungs. IAV HA mRNA expression
was normalized to the mRNA expression of mouse HPRT. The
quantities are shown as mean ± SE. ∗∗P<0.01 (Student’s t-test).
We conﬁrmed that Brazilian green propolis extracts
(PWE and PEE) have anti-inﬂuenza activities. Here, we
also hypothesized that their mode of action at least par-
tially includes two mechanisms: an unknown cytoprotective
mechanism [31] and the enhancement of viral clearance
via TRAIL overexpression. We hypothesize that both are
induced by 3,4-diCQA and/or unknown active constituents
of Brazilian green propolis.
Animportantpointregardingourhypothesisconcerning
the anti-inﬂuenza eﬀects of propolis or its constituent,
3,4-diCQA, is that it might trigger or enhance the self-
defense machineries of the host. Although viruses can easily
become resistant to anti-inﬂuenza drugs, such as oseltamivir,
that directly target viral proteins [4, 5], it would be more
diﬃcult for viruses to become resistant to antiviral agents
whose target molecules are host molecules or machineries.
Therefore,healthsupplementssuchaspropolismaybeuseful
as an alternative strategy for protection against inﬂuenza
virus infections.
ManytraditionalChinesemedicinalherbsappeartohave
potential anti-inﬂuenza eﬀects [46], but their mechanisms6 Evidence-Based Complementary and Alternative Medicine
Table 2: Concentrations and molecular weights of the constituents











Chlorogenic acid 2.7–3.6 0.6–0.8 354.3
Caﬀeic acid 0.2 0.1–0.6 180.2
3,5-dicaﬀeoylquinic
acid 4.3–4.9 2.4–2.7 516.5
3,4-dicaﬀeoylquinic
acid 3.3–6.1 1.9–3.5 516.5
4,5-dicaﬀeoylquinic
acid —# —# 516.5
3,4,5-tricaﬀeoylquinic
acid 0.2 0.6 678.6
Artepillin C 0.2–0.6 11.4–14.0 300.4
Baccharin 0.0 6.8 562.6
Drupanin 0.1 1.8 232.3
Isosakuranetin —# 1.2 286.3
p-coumaric acid 3.7 2.3–2.5 164.2
Ferulic acid 0.1 0.0–0.1 194.2
Quinic acid —# —# 192.2
#Data not available.
are not well understood. Our ﬁndings show that PWE and
PEE and their constituent, 3,4-diCQA, may be useful as a
potentleadcompoundforanti-inﬂuenzamedicine.Thismay
promote research into anti-inﬂuenza medicine developed
from traditional substances.
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